NCT05297968View on ClinicalTrials.gov

Study on the Human Bioequivalence of Oseltamivir Phosphate For Oral Suspension

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

June 6, 2021

Study Completion Date

June 27, 2021

Conditions
Healthy Subjects
Interventions
DRUG

Oseltamivir Phosphate For Oral Suspension/Tamiflu

the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension/Tamiflu 75mg (6mg/ml,12.5ml)

DRUG

Oseltamivir Phosphate For Oral Suspension

the subjects randomly received single oral administration of Oseltamivir Phosphate For Oral Suspension 75mg (6mg/ml,12.5ml)

Trial Locations (1)

266003

Phase I Clinical Research Center, Qingdao

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER